3,477 press releases in English indexed under healthcare.
Sitero today released three Ash agentic workflows simultaneously, covering clinical study setup, continuous data review, and portfolio-level insights, all governed by human review at every step. CORAL GABLES, Fla., Aug. 18, 2026 -- Sitero, a clinical research organization...
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
ISELIN, N.J, August 18, 2026--Ephicacy today announced the appointment of Dr. Shekhar Thumake as head of AI, a new role that reflects the company’s growing investment in artificial intelligence across its biometrics operations.
STUART, Fla., August 18, 2026--Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commercializ
ATHLONE, Ireland, August 18, 2026--Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma
BALLERUP, Denmark, August 18, 2026--LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, today announces that it has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for EPP and XLP.
LUND, Sweden, Aug. 18, 2026 -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...
WATERTOWN, Mass., August 18, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ market. The IPO marks a significant milestone as the company accelerates the development and global commercialization of its proprietary vascular stabilization pipeline.
NEW YORK, Aug 18, 2026 - Broad Investment Securities LLC, a U.S. SEC-registered investment adviser, has issued an independent fundamental research report on Tokyo Lifestyle Co., Ltd. (Nasdaq: TKLF), examining the Japanese consumer-products distributor’s business model, financial trajectory, channel mix and international expansion. Tokyo Lifestyle, formerly Yoshitsu Co., Ltd., operates as a retailer and wholesaler of Japanese beauty and health products, general merchandise, luxury goods, electronics and collectible cards. The company reaches end markets through four channels—company-operated stores, franchise outlets, wholesale distribution and cross-border e-commerce—across Japan, Hong Kong, Southeast Asia, North America, the UK and Australia. Its assortment spans roughly 69,800 SKUs. Supplier relationships include major Japanese brands such as Shiseido, Kao and Kose. The company also manages proprietary and licensed brands including Tokyo Lifestyle, Hare no Ryohin and REIWATAKIYA. In 2025 it began private-label product development and entered a strategic collaboration with an affiliate of Tasly Group aimed at joint research, development and global distribution of health products. As of the fiscal year ended March 31, 2026, Tokyo Lifestyle reported nine franchise partners operating 11 stores in the United States, the UK, Hong Kong, Thailand, Vietnam and Japan. Hong Kong continues to serve as the primary logistics and distribution hub linking Japanese supply chains to overseas markets. Net revenue for FY2026 rose 77.6% year-on-year to $373.2 million, the highest level since the company’s January 2022 Nasdaq listing. Revenue expanded from approximately $195.7 million in FY2024 to $210.1 million in FY2025 before accelerating to $373.2 million. The increase was driven principally by faster growth in the franchise and wholesale channels and by an expanded contribution from luxury goods, consistent with management’s stated transition from an asset-heavy company-operated model toward a lighter franchise-and-wholesale structure. Gross margin contracted from 11.4% in FY2025 to 7.5% in FY2026. Net income attributable to the company was about $0.72 million, or basic earnings per share of $0.02. The margin compression reflects the rising weighting of franchise and wholesale sales, which typically generate lower unit margins in exchange for greater scale and reduced capital intensity. The company remains in the investment phase of this strategic shift; the path to sustained profitability is still evolving. Geographic mix continued to internationalize. Japan accounted for 52.9% of FY2026 revenue, down from 70.5% a year earlier, while Hong Kong and other overseas markets rose to 47.1% from 29.5%. Total assets increased to $233.6 million from $157.8 million, of which accounts receivable stood at $186.8 million. Operating cash flow was negative during the period, primarily reflecting the working-capital build associated with expansion. At the July 29, 2026 close, the shares traded at $2.025 per ADS, implying a market capitalization of approximately $8.57 million, a trailing price-to-earnings ratio of about 11.96 and a price-to-book ratio of roughly 0.21. As a micro-cap issuer, Tokyo Lifestyle remains subject to Nasdaq continued-listing requirements as well as balance-sheet and cash-flow considerations, points the research note addresses directly. Overall, the report positions Tokyo Lifestyle as a relatively scarce Nasdaq-listed Japanese cross-border consumer-products platform with above-average top-line growth and a distinctly international revenue profile, while underscoring the operational and financial characteristics typical of a micro-cap company still executing a structural transition. For more information, please contact: Golden Fleece Cross-border Consulting Co., Limited Email: heidiho@goldenfleece.hk
Round exclusively led by Qiming Venture Partners; proceeds to fund China registration trial and overseas early-stage clinical development SHANGHAI and HANGZHOU, China, Aug. 17, 2026 -- Enginprime Medical ("Enginprime" or the "Company"), a developer of percutaneous ventricular...
Company will highlight medical silicone pump tubing, Para-tubing solutions for ophthalmic applications, and PTA/PTCA precision interventional tubing technologies to support medical device innovation Company will highlight medical silicone pump tubing, Para-tubing solutions for ophthalmic applications, and PTA/PTCA precision interventional tubing technologies to support medical device innovation
Access cost-effective spine surgery with advanced medical expertise, modern facilities, and compassionate care for international patients.